

---

**Ischemic Stroke  
Patient Care:  
*tPA Use in 2007***

Edward P. Sloan, MD, MPH, FACEP 

---

**FERNE Special Presentation**



[www.ferne.org](http://www.ferne.org)

Edward P. Sloan, MD, MPH, FACEP 

---

**IEME  
Current Concepts in  
Emergency Care**

***Maui, HI  
December 6, 2006***

Edward P. Sloan, MD, MPH, FACEP 

---

**Edward P. Sloan, MD, MPH FACEP**

*Professor*

*Department of Emergency Medicine  
University of Illinois College of Medicine  
Chicago, IL*

Edward P. Sloan, MD, MPH, FACEP 

---

**Attending Physician  
Emergency Medicine**

*University of Illinois Hospital  
Our Lady of the Resurrection Hospital*

**Chicago, IL**

Edward P. Sloan, MD, MPH, FACEP 

---

**Disclosures**

- Consultant to Baxter, Eisai, King Pharma, Novo Nordisk
- Speaker's bureau Eisai
- FERNE President and Board Chair
- ACEP Clinical Policy Committee
- FERNE support from Astra Zeneca, Eisai, Novo Nordisk, UCB Pharma

Edward Sloan, MD, MPH, FACEP 

## Thank You

- IEME
- Marvin Wayne, MD (and Joan)
- The FERNE staff:
  - Charri, Carla, Jonathan, Li
- Prior FERNE supporters
- All of you

Edward Sloan, MD, MPH, FACEP



## Clinical Situation

- tPA has been approved for 10+ years
- There is still much discussion, if not outright controversy
- It is the standard of care
- When is it the standard of care?
- Why is it the standard of care?
- How should it be used in clinical EM practice?

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- tPA has proven clinical efficacy based on paired phase III clinical trials

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- tPA has proven clinical efficacy based on paired phase III clinical trials
- tPA has proven clinical effectiveness based on multiple phase IV reports of clinical use

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- tPA has proven clinical efficacy based on paired phase III clinical trials
- tPA has proven clinical effectiveness based on multiple phase IV reports of clinical use
- tPA effectiveness is suggested by publications of meta-analysis data

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- tPA has proven clinical efficacy based on paired phase III clinical trials
- tPA has proven clinical effectiveness based on multiple phase IV reports of clinical use
- tPA effectiveness is suggested by publications of meta-analysis data
- Reanalysis of the NINDS clinical trials confirms initial clinical efficacy report

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- Emergency Medicine organizations suggest that there is likely clinical efficacy in selected patient populations

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- Emergency Medicine organizations suggest that there is likely clinical efficacy in selected patient populations
- Legal input suggests that patients, in general, understand this therapy to be the standard of care that offers benefit

Edward Sloan, MD, MPH, FACEP



## Clinical tPA Facts

- Emergency Medicine organizations suggest that there is likely clinical efficacy in selected patient populations
- Legal input suggests that patients, in general, understand this therapy to be the standard of care that offers benefit
- Many institutions and EM physicians successfully use this therapy

Edward Sloan, MD, MPH, FACEP



## Clinical Questions

- Based on these facts, is there still concern about the use of tPA in selected patients?
- What is the basis for this concern?
- What more can be studied or taught regarding this stroke therapy?
- What could FERNE specifically do in order to improve your EM clinical practice for these patients?

Edward Sloan, MD, MPH, FACEP



***Thank you.***

**[www.ferne.org](http://www.ferne.org)**  
**[ferne@ferne.org](mailto:ferne@ferne.org)**

**[edsloan@uic.edu](mailto:edsloan@uic.edu)**  
**312 413 7490**

ferne\_ierne\_2006\_sloan\_tpauser\_120606\_finalcd  
12/14/2006 6:12 PM

Edward P. Sloan, MD, MPH, FACEP



***[www.ferne.org](http://www.ferne.org)***

Edward P. Sloan, MD, MPH, FACEP

